X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
agammaglobulinaemia tyrosine kinase (353) 353
humans (308) 308
animals (238) 238
protein-tyrosine kinases - genetics (169) 169
mice (163) 163
protein-tyrosine kinases - metabolism (160) 160
index medicus (134) 134
x-linked agammaglobulinemia (127) 127
immunology (121) 121
male (116) 116
agammaglobulinemia - genetics (91) 91
signal transduction (91) 91
female (82) 82
mutation (80) 80
activation (77) 77
btk (76) 76
phosphorylation (76) 76
biochemistry & molecular biology (74) 74
x chromosome (73) 73
protein-tyrosine kinases - antagonists & inhibitors (72) 72
molecular sequence data (67) 67
protein-tyrosine kinases - physiology (64) 64
bruton's tyrosine kinase (63) 63
b-lymphocytes - immunology (61) 61
hemic and lymphatic diseases (58) 58
expression (57) 57
mice, inbred c57bl (52) 52
hematology (51) 51
tyrosine (51) 51
adult (50) 50
brutons tyrosine kinase (50) 50
cell line (49) 49
amino acid sequence (46) 46
genetic linkage (46) 46
ibrutinib (46) 46
b-lymphocytes - enzymology (45) 45
base sequence (45) 45
oncology (43) 43
protein-tyrosine kinases - chemistry (43) 43
enzyme activation (42) 42
gene (42) 42
protein-tyrosine kinases - deficiency (41) 41
agammaglobulinaemia tyrosine kinase - antagonists & inhibitors (40) 40
cells, cultured (38) 38
mice, knockout (37) 37
immunodeficiency (36) 36
protein kinase inhibitors - pharmacology (36) 36
protein kinase inhibitors - therapeutic use (36) 36
pyrimidines - therapeutic use (36) 36
cell biology (35) 35
leukemia, lymphocytic, chronic, b-cell - drug therapy (35) 35
receptors, antigen, b-cell - metabolism (35) 35
b-lymphocytes - metabolism (34) 34
chronic lymphocytic-leukemia (34) 34
pyrazoles - therapeutic use (33) 33
mice, inbred cba (32) 32
multidisciplinary sciences (31) 31
pyrimidines - pharmacology (31) 31
x-linked agammaglobulinaemia (31) 31
agammaglobulinemia - immunology (30) 30
middle aged (30) 30
protein-tyrosine kinase (30) 30
research (30) 30
article (28) 28
leukemia (28) 28
ph domain (28) 28
receptor (28) 28
child (27) 27
immune system diseases (27) 27
lymphoma (27) 27
protein tyrosine kinase (27) 27
receptors, antigen, b-cell - physiology (27) 27
agammaglobulinemia - enzymology (26) 26
protein (26) 26
signal transduction - immunology (26) 26
treatment outcome (26) 26
aged (25) 25
apoptosis (25) 25
lymphocyte activation (25) 25
lymphomas (25) 25
point mutation (25) 25
syk kinase (25) 25
b-cells (24) 24
b-lymphocytes - cytology (24) 24
mice, mutant strains (24) 24
tyrosine kinase (24) 24
antigen receptor (23) 23
care and treatment (23) 23
child, preschool (23) 23
intracellular signaling peptides and proteins (23) 23
protein kinase inhibitors - administration & dosage (23) 23
protein kinase inhibitors - adverse effects (23) 23
pyrazoles - pharmacology (23) 23
agammaglobulinaemia tyrosine kinase - metabolism (22) 22
b lymphocytes (22) 22
cell differentiation (22) 22
cells (22) 22
chickens (22) 22
flow cytometry (22) 22
phospholipase c gamma (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Molecular Cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, p. 57
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of... 
Chronic lymphocytic leukemia | Tumor microenvironment | B cell receptor signaling | Leukemia | Chemokine receptor | B cell development | Bruton's tyrosine kinase | Lymphoma | Ibrutinib | SIGNALING PATHWAYS | BIOCHEMISTRY & MOLECULAR BIOLOGY | X-LINKED AGAMMAGLOBULINEMIA | FACTOR-KAPPA-B | ATRIAL-FIBRILLATION | BTK INHIBITOR IBRUTINIB | TEC KINASE | ONCOLOGY | THERAPEUTIC TARGET | CHRONIC LYMPHOCYTIC-LEUKEMIA | TUMOR-ASSOCIATED MACROPHAGES | BETA-GAMMA-SUBUNITS | Leukemia, B-Cell - metabolism | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Tumor Microenvironment | Leukemia, B-Cell - etiology | Receptors, Antigen, B-Cell - metabolism | Molecular Targeted Therapy | Biomarkers, Tumor | Cell Differentiation - genetics | Agammaglobulinaemia Tyrosine Kinase - metabolism | Cell Transformation, Neoplastic - genetics | Leukemia, B-Cell - drug therapy | Agammaglobulinaemia Tyrosine Kinase - chemistry | B-Lymphocytes - pathology | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, B-Cell - etiology | Bone Marrow | B-Lymphocytes - metabolism | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - metabolism | Lymphopoiesis - ethics | Leukemia, B-Cell - pathology | Treatment Outcome | Cell Transformation, Neoplastic - metabolism | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Lymphoma, B-Cell - pathology | Agammaglobulinaemia Tyrosine Kinase - genetics | Protein Kinase Inhibitors - pharmacology | Care and treatment | Usage | Lymphomas | Research | Chemokines | Cancer
Journal Article
Blood, ISSN 0006-4971, 04/2017, Volume 129, Issue 16, pp. 2224 - 2232
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3734 - 3743
Purpose: Ibrutinib inhibits Bruton tyrosine kinase (BTK) by irreversibly binding to the Cys-481 residue in the enzyme. However, ibrutinib also inhibits several... 
B-CELLS | ACTIVATION | ONCOLOGY | INITIAL THERAPY | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | PCI-32765 | RECEPTOR | OPEN-LABEL | SRC FAMILY KINASES | EXPRESSION | Humans | Pyrazines - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Benzamides - administration & dosage | Protein-Tyrosine Kinases - genetics | T-Lymphocytes - drug effects | Caspase 3 - genetics | Benzamides - adverse effects | Pyrazoles - adverse effects | Pyrimidines - administration & dosage | src-Family Kinases - antagonists & inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Signal Transduction - drug effects | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - adverse effects | Pyrimidines - adverse effects | Cell Line, Tumor | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Poly (ADP-Ribose) Polymerase-1 - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Phosphorylation | Leukocyte migration | Downstream effects | Leukemia | Carbon tetrachloride | Homology | Lymphocytes T | Kinases | Caspase-3 | Biological effects | Lymphocytes | Protein-tyrosine kinase | Downstream | Tyrosine | Chronic lymphatic leukemia | Extracellular signal-regulated kinase | Caspase | Poly(ADP-ribose) polymerase | Cultures | CCL3 protein | Lymphatic leukemia | CCL4 protein | Patients | Bruton's tyrosine kinase | Signaling | Inhibitors | Experimental design | Cell death | Cell migration | Chemokines | Cancer | ibrutinib | apoptosis | Bruton tyrosine kinase | chronic lymphocytic leukemia | acalabrutinib
Journal Article
Cancer Discovery, ISSN 2159-8274, 09/2017, Volume 7, Issue 9, pp. 1018 - 1029
Journal Article
Leukemia, ISSN 0887-6924, 10/2017, Volume 31, Issue 10, pp. 2075 - 2084
Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial... 
MULTICENTER | CLL CELLS | THERAPY | ONCOLOGY | MCL-1 | IBRUTINIB | RESISTANCE | BTK | LYMPHOMA | OPEN-LABEL | HEMATOLOGY | ABT-199 | Peptide Fragments | Pyrazoles - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Pyrazines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - agonists | Neoplasm Proteins - antagonists & inhibitors | Pyrazines - therapeutic use | Molecular Targeted Therapy | Benzamides - administration & dosage | Benzamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sulfonamides - agonists | Benzamides - pharmacology | Proto-Oncogene Proteins | Pyrazoles - pharmacology | Pyrimidines - administration & dosage | Bcl-2-Like Protein 11 - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Clinical Trials as Topic | Mitochondria - drug effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bcl-2-Like Protein 11 - biosynthesis | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Protein Kinase Inhibitors - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Enzymes | Chronic lymphocytic leukemia | Care and treatment | Development and progression | Genetic aspects | Regulation | Drug resistance | Health aspects | Killing | Tyrosine | Drugs | Medical research | Chronic lymphatic leukemia | Bcl-2 protein | Leukemia | Clinical trials | Priming | Lymphatic leukemia | Patients | Bruton's tyrosine kinase | Mitochondria | Inhibitors | Cell death | Sensitivity enhancement | Inhibition | Pretreatment | Protein-tyrosine kinase | BIM protein | Apoptosis
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 11/2017, Volume 363, Issue 2, pp. 240 - 252
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 10/2017, Volume 140, Issue 4, pp. 985 - 987
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 07/2018, Volume 59, Issue 7, pp. 1554 - 1564
Journal Article
Blood, ISSN 0006-4971, 06/2018, Volume 131, Issue 24, pp. 2605 - 2616
Journal Article
Bioconjugate Chemistry, ISSN 1043-1802, 05/2018, Volume 29, Issue 5, pp. 1640 - 1645
Journal Article